RenovoRx Inc

Chart & performance

D1W1MN

P/E

—

P/S

53.36

EPS

—

Div yield, %

—

Shrs. gr., 5y

15.32%

Rev. gr., 5y

Revenues

+2,511.63%

Net income

-11m

L+26.71%

CFO

-11m

L+20.25%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Key people

Kamran Najmabadi

Founder, Chief Operating Officer, Chief Technology Officer

Scott Gellert

Director of Clinical Research

Imtiaz Qureshi

Director of Imaging

Shaun R. Bagai

Chief Executive Officer and Director · since 2014

URL

https://renovorx.com/

IPO date

Aug 17, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT